Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
about
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
description
im August 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 07 August 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2018
@uk
name
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@en
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@nl
type
label
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@en
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@nl
prefLabel
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@en
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@nl
P2093
P2860
P921
P1476
Phase II randomized, double-bl ...... istant prostate cancer (mCRPC)
@en
P2093
Amir Mortazavi
James Wade
John Wright
Jorge A Garcia
Miguel Villalona-Calero
Nancy Dawson
Robert Dreicer
Roberto Pili
Russell Szmulewitz
P2860
P2888
P304
P356
10.1007/S10637-018-0630-9
P407
P50
P577
2018-08-07T00:00:00Z